A citation-based method for searching scientific literature

Shinichi Komiyama, Kazuyoshi Kato, Yuki Inokuchi, Hirokuni Takano, Takashi Matsumoto, Atsushi Hongo, Mikiko Asai-Sato, Atsushi Arakawa, Shoji Kamiura, Tsutomu Tabata, Nobuhiro Takeshima, Toru Sugiyama. Int J Clin Oncol 2019
Times Cited: 24







List of co-cited articles
171 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
58

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
58

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
45

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
37

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
243
37

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
606
29

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
364
25

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
72
25

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
51
25

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010
20

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Amit M Oza, Frédéric Selle, Irina Davidenko, Jacob Korach, Cesar Mendiola, Patricia Pautier, Ewa Chmielowska, Aristotelis Bamias, Andrea DeCensi, Zanete Zvirbule,[...]. Int J Gynecol Cancer 2017
33
20

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson. Gynecol Oncol 2018
22
22

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
304
20

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Sean Kehoe, Jane Hook, Matthew Nankivell, Gordon C Jayson, Henry Kitchener, Tito Lopes, David Luesley, Timothy Perren, Selina Bannoo, Monica Mascarenhas,[...]. Lancet 2015
570
16

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
16

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, Hirofumi Michimae, Eizo Kimura, Daisuke Aoki, Toshiko Jobo, Shoji Kodama, Fumitoshi Terauchi,[...]. Lancet Oncol 2013
271
16

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
John K Chan, Mark F Brady, Richard T Penson, Helen Huang, Michael J Birrer, Joan L Walker, Paul A DiSilvestro, Stephen C Rubin, Lainie P Martin, Susan A Davidson,[...]. N Engl J Med 2016
201
16

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
705
16

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Jung-Yun Lee, Jeong-Yeol Park, Sang Yoon Park, Jeong-Won Lee, Jae Weon Kim, Yong Beom Kim, Dae Hoon Jeong, Kwang-Beom Lee, Tae-Hun Kim, In Ho Lee,[...]. Gynecol Oncol 2019
13
30

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
26
16

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Seiji Mabuchi, Chiaki Kawase, Deborah A Altomare, Kenichirou Morishige, Kenjiro Sawada, Masami Hayashi, Masahiko Tsujimoto, Mareo Yamoto, Andres J Klein-Szanto, Russell J Schilder,[...]. Clin Cancer Res 2009
117
16

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers.  2017
446
16

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Aikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki,[...]. Int J Gynecol Cancer 2014
74
16

Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
Hiroko Machida, Koji Matsuo, Wataru Yamagami, Yasuhiko Ebina, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kanauchi, Satoru Nagase, Takayuki Enomoto, Mikio Mikami. Gynecol Oncol 2019
33
16

Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Masashi Takano, Hiroshi Tsuda, Toru Sugiyama. J Exp Clin Cancer Res 2012
51
16

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
M Takano, Y Kikuchi, N Yaegashi, K Kuzuya, M Ueki, H Tsuda, M Suzuki, J Kigawa, S Takeuchi, H Tsuda,[...]. Br J Cancer 2006
186
16

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord,[...]. Gynecol Oncol 2017
35
16

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Hiroaki Itamochi, Junzo Kigawa, Naoki Terakawa. Cancer Sci 2008
171
16

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, Virginie Fourchotte, Christophe Pomel, Pierre-Emmanuel Colombo, Elsa Kalbacher, Sandrine Martin-Francoise,[...]. Eur J Cancer 2017
41
12

Development and validation of a predictive model for chemotherapy-associated thrombosis.
Alok A Khorana, Nicole M Kuderer, Eva Culakova, Gary H Lyman, Charles W Francis. Blood 2008
12

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade-Lauraine, Sabino De Placido, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici,[...]. Lancet Oncol 2014
206
12

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
680
12

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
609
12

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A Burger, Deborah Armstrong, Robert Wenham,[...]. J Clin Oncol 2007
536
12

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W P McGuire, W J Hoskins, M F Brady, P R Kucera, E E Partridge, K Y Look, D L Clarke-Pearson, M Davidson. N Engl J Med 1996
12

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
12

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Kristin K Zorn, Tomas Bonome, Lisa Gangi, Gadisetti V R Chandramouli, Christopher S Awtrey, Ginger J Gardner, J Carl Barrett, Jeff Boyd, Michael J Birrer. Clin Cancer Res 2005
274
12

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Rowan E Miller, Rachel Brough, Ilirjana Bajrami, Chris T Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan,[...]. Mol Cancer Ther 2016
50
12

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Hiroaki Itamochi, Tetsuro Oishi, Nao Oumi, Satoshi Takeuchi, Kosuke Yoshihara, Mikio Mikami, Nobuo Yaegashi, Yasuhisa Terao, Kazuhiro Takehara, Kimio Ushijima,[...]. Br J Cancer 2017
37
12

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
225
12

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
357
12

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
12

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
12

Clear cell carcinoma of the ovary: a review of the literature.
Marcela G del Carmen, Michael Birrer, John O Schorge. Gynecol Oncol 2012
143
12

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
54
12

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Takayuki Enomoto, Daisuke Aoki, Kana Hattori, Masahisa Jinushi, Junzo Kigawa, Nobuhiro Takeshima, Hitoshi Tsuda, Yoh Watanabe, Kosuke Yoshihara, Toru Sugiyama. Int J Gynecol Cancer 2019
32
12

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Joseph J Caumanns, G Bea A Wisman, Katrien Berns, Ate G J van der Zee, Steven de Jong. Biochim Biophys Acta Rev Cancer 2018
40
12

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan,[...]. Clin Cancer Res 2018
23
13

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Seiji Mabuchi, Chiaki Kawase, Deborah A Altomare, Kenichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J Klein-Szanto,[...]. Mol Cancer Ther 2010
53
12

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Robert L Coleman, Nick M Spirtos, Danielle Enserro, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Jae-Weon Kim, Sang-Yoon Park, Byoung-Gie Kim, Joo-Hyun Nam,[...]. N Engl J Med 2019
83
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.